£2K to invest? I’d check out these 2 high-flying FTSE 250 growth stocks

These FTSE 250 (INDEXFTSE:UKX) growth stocks are up more than 65% in the last year alone, and are well worth a look.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Too many investors overlook the FTSE 250, but they shouldn’t. The index of medium-sized UK companies is packed full of gems which, by dint of being smaller can grow faster, with many set to become the blue-chips of the future.

The following two saw their share prices climb more than two thirds last year, and they could have further to go this year.

Polypipe Group

Polypipe Group (LSE: PLP), which delivers sustainable water and climate management solutions for the built environment, returned almost 70% to shareholders in 2019, despite what it called tough trading conditions.

Its most recent update, from October, talked up a “resilient performance” in tough markets, but group revenue, nonetheless, rose 4.3% to £381.7m, with operating margins up 30 basis points, boosted by “margin accretive acquisitions and strong cost controls.”

This was before the general election, during a time when Brexit uncertainty squeezed domestic firms like this one, so it will be interesting to see if it benefits from any Boris bounce. The £1.1bn group has several factors in its favour, which it identifies as the “structural housing shortage, historically low interest rates, real wage growth, and near full employment.” 

If you’re bullish on the UK economy, this could be a good way to play its recovery. Despite its strong share price growth, the Polypipe share price isn’t too expensive, trading at 17.4 times future earnings.  

Growth forecasts also look positive, with 8% expected this year, and 7% in 2021. You get a forecast yield of 2.5%, although this is primarily a growth stock, and one that may repay further digging.

Avast

Cyber-security specialist Avast (LSE: AVST) also flew in 2019, as it continues to benefit from operating in a rapidly growing area, with the market forecast to be worth $170bn a year by 2022.

Unfortunately, the £4.6bn group hit a stumbling block in January, when it was forced to close down 2013 acquisition Jumpshot, which had been caught scraping browsing data from the company’s customers without full permission, and selling it to advertisers including Google, Yelp and Microsoft.

The hugely embarrassing revelation, exposed by Motherboard and PCMag, knocked the Avast share price down 25%, although it has picked up 16% in the last week. Given that Jumpshot harvested millions of dollars from clients, future revenues could take a hit, although management said Jumpshot produced just $36m of full-year adjusted 2019 revenue, against $862.8m for the group.

The closure should therefore have little impact on its full-year 2019 results, which are line with expectations. Customer trust may prove harder to rebuild, although given the minimal long-term impact that the big data scandal had on Facebook and others, investors may not be too worried.

Avast is a top-five antivirus provider with more than 400m customers worldwide, and expects full-year organic billings to be up 10.2% to $900.7m.

Analyst Peel Hunt recently said its stock may be overvalued, given that it now faces threats from Windows Defender, and the move towards cloud-based services. Avast still has massive potential, but it can’t afford further slip-ups.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Harvey Jones has no position in any of the shares mentioned. The Motley Fool UK has recommended Polypipe. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

After it crashed 25%, should I buy this former stock market darling in my Stocks and Shares ISA?

Harvey Jones has a big hole in his Stocks and Shares ISA that he is keen to fill. Should he…

Read more »

happy senior couple using a laptop in their living room to look at their financial budgets
Investing Articles

How’s the dividend forecast looking for Legal & General shares in 2025 and beyond?

As a shareholder, I like to keep track of the potential dividend returns I could make from my Legal &…

Read more »

artificial intelligence investing algorithms
Investing Articles

Could buying this stock with a $7bn market cap be like investing in Nvidia in 2010?

Where might the next Nvidia-type stock be lurking in today's market? Our writer takes a look at one candidate with…

Read more »

Investing Articles

Is GSK a bargain now the share price is near 1,333p?

Biopharma company GSK looks like a decent stock to consider for the long term, so is today's lower share price…

Read more »

Snowing on Jubilee Gardens in London at dusk
Investing Articles

Could December be a great month to buy UK shares?

Christopher Ruane sees some possible reasons to look for shares to buy in December -- but he'll be using the…

Read more »

Young mixed-race couple sat on the beach looking out over the sea
Investing Articles

Sticking to FTSE shares, I’d still aim for a £1,000 monthly passive income like this!

By investing in blue-chip FTSE shares with proven business models, our writer hopes he can build sizeable passive income streams…

Read more »

Growth Shares

BT shares? I think there are much better UK stocks for the long term

Over the long term, many UK stocks have performed much better than BT. Here’s a look at two companies that…

Read more »

British Pennies on a Pound Note
Investing Articles

After a 540% rise, could this penny share keep going?

This penny share has seen mixed fortunes in recent years. Our writer looks ahead to some potentially exciting developments in…

Read more »